Company intelligence / Profile preview

Onconome

Redmond, Washington, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Onconome developed and published encouraging data on a new blood test for colon cancer, focusing on early detection using novel biomarkers. The company was dedicated to the discovery and commercialization of products for early diagnosis of cancer, with a particular emphasis on non-invasive blood tests. There is no recent information indicating ongoing operations or product commercialization after initial research publications from the early 2000s.

Therapeutic areas: Oncology
Modalities: Diagnostic testBiomarker-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

Kirlan Venture Capital

Beyond the preview

Go deeper on Onconome.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Onconome.

Explore the full profile